Related Experiment Videos
Guanazole (NSC-1895)--a phase I clinical study
Cancer Chemotherapy Reports
|November 1, 1975
Summary
This phase I study evaluated two guanazole schedules. Bone marrow suppression was the main toxicity, worsened by prior treatments and repeated dosing, indicating further research is warranted.
Area of Science:
- Oncology
- Clinical Pharmacology
- Pharmacodynamics
Background:
- Guanazole is an antineoplastic agent.
- Phase I studies are crucial for evaluating novel cancer therapies.
Purpose of the Study:
- To assess the safety and tolerability of two different dosing schedules of guanazole in cancer patients.
- To identify dose-limiting toxicities and preliminary efficacy signals.
Main Methods:
- Phase I clinical trial design.
- Two guanazole administration schedules: prolonged 5-day infusion and twice-weekly IV bolus.
- Analysis of 97 prolonged infusion and 42 bolus treatment observations for toxic effects.
Main Results:
- Bone marrow suppression was the primary toxicity, more severe with prior chemotherapy/radiotherapy and repeated guanazole doses.
- Leukocyte counts were more affected than platelet counts.
- Partial responses observed in 4 patients (2 lung carcinoma, 1 prostate carcinoma, 1 melanoma).
Conclusions:
- Guanazole exhibits dose-dependent toxicity, primarily affecting bone marrow.
- The observed partial responses suggest potential efficacy warranting further investigation.
- Further Phase II clinical studies of guanazole are indicated.